Vaccinex Inc - VCNX STOCK NEWS

Vaccinex (VCNX) has announced its decision to voluntarily delist its common stock from the Nasdaq Stock Market. This follows a suspension of trading since December 18, 2024, and a notice dated December 16, 2024, from the Nasdaq Hearings Panel determining to delist the company's securities.

The biotechnology company plans to file a Form 25 with the SEC around March 17, 2025, to formally remove its listing. Despite the delisting, Vaccinex intends to continue developing its lead product, pepinemab, targeting Alzheimer's disease and cancer treatments through partnerships, grants, and alternative financing methods.

Vaccinex (VCNX) received a delisting notification from Nasdaq on December 16, 2024, due to failure to maintain the required minimum of $2.5 million in stockholders' equity under Nasdaq Listing Rule 5550(b)(1). Trading of VCNX common stock will be suspended on Nasdaq effective December 18, 2024. Following the suspension, the company's shares are expected to be quoted on the OTC Markets Group under the same symbol 'VCNX'.

Vaccinex (VCNX) reported Q3 2024 financial results and provided updates on its Alzheimer's disease program. The company reported final data from its SIGNAL-AD clinical trial, showing that pepinemab treatment slowed cognitive decline in patients with early signs of cognitive deficits. Cash and equivalents were $2.9 million as of September 30, 2024. The company recently completed a private placement raising $2.15 million and received approximately $6.2 million from warrant exercises. Q3 net loss was $5.7 million or $(2.83) per share. The company is currently facing Nasdaq listing compliance issues and has submitted a plan to maintain its listing.

Vaccinex (NASDAQ: VCNX) announced multiple proprietary project agreements with major pharmaceutical companies including Amgen, Merck, Chugai, and others for using its ActivMAb® technology platform. The technology enables expression of complex proteins for antibody discovery, particularly useful for developing immunotherapies. The company will also provide materials to strategic partners like Charles River Labs and OmniAb to support their antibody discovery programs.

Additionally, Vaccinex will present data on successful antibody discovery campaigns at the Society for Immunotherapy of Cancer's 29th Annual Meeting in Houston. The first clinical candidate using this technology (CHS-114) is currently in development by Coherus Biosciences for cancer immunotherapy.

Vaccinex (NASDAQ: VCNX) announced new biomarker data showing that pepinemab enhanced clinical activity of immune checkpoint inhibitors in HPV-negative head and neck cancer (HNSCC). Data from two studies, the Phase 2 KEYNOTE-B84 and a neoadjuvant treatment study, demonstrated that pepinemab combination treatments induced mature lymphoid aggregates correlating with clinical benefit in immunotherapy resistant tumors. The findings will be presented at the Society for Immunotherapy of Cancer's Annual Meeting on November 8th, 2024.

The research suggests pepinemab can overcome limitations of immune checkpoint inhibitors, particularly in patients who typically don't benefit from immune checkpoint monotherapy.

Vaccinex (VCNX) announced new findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. The study revealed that pepinemab treatment inhibits the expression of plasma GFAP and p-tau 217 biomarkers during Mild Cognitive Impairment (MCI). The treatment showed promising trends in slowing cognitive decline in mild dementia patients with MMSE scores of 22-26. Proteomic analysis of Cerebrospinal Fluid identified several proteins typically increasing during AD progression that were inhibited by pepinemab. Additionally, using a Brain-Chip model, pepinemab demonstrated ability to inhibit or reverse damage caused by toxic alpha synuclein aggregates, suggesting potential applications in other neurodegenerative diseases.

Vaccinex (NASDAQ: VCNX) announced upcoming presentation of new efficacy and safety data from its SIGNAL-AD phase 1b/2 trial of pepinemab for Alzheimer's disease at the CTAD Conference in Madrid on October 31, 2024. The study focuses on pepinemab's ability to block SEMA4D, a molecule highly upregulated in damaged neurons during AD progression. The treatment aims to prevent harmful astrocyte activation that may accelerate disease progression. Key outcomes include impacts on cognitive decline and disease progression biomarkers. Notably, pepinemab shows potential benefits for brain vascular integrity, addressing a common concern with current AD treatments that can cause microhemorrhages.

Vaccinex (Nasdaq: VCNX), a clinical-stage biotech company focusing on neurodegenerative disease treatment, has announced the exercise of outstanding warrants resulting in $6.2 million in gross proceeds. The transaction involves:

1. Immediate exercise of warrants to purchase 1,067,492 shares at $5.636 per share
2. Issuance of 827,483 shares and pre-funding of 240,009 shares
3. New warrants issued for up to 1,601,238 additional shares at $5.636 per share, expiring in 5 years

Notably, entities affiliated with the CEO and Board Chairman accounted for 51% of the securities in the transaction. The closing is expected on September 18, 2024, subject to customary conditions.

Vaccinex (VCNX) has reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in early-stage Alzheimer's disease (AD). The study showed a statistically significant difference (p=0.0297) in FDG-PET signal in the medial temporal cortex after 12 months of treatment compared to placebo. Pepinemab was well-tolerated in AD patients.

Key findings include:

• Reduction in blood levels of GFAP (astrocyte reactivity marker) and p-tau 217 (neuronal damage marker) in patients with Mild Cognitive Impairment (MCI) due to AD
• Apparent slowing of cognitive decline in MCI patients, as measured by iADRS and ADAS-Cog 13 assessments
• No discernible effect on biomarkers or cognitive decline in patients with early dementia

Vaccinex aims to pursue a development partnership for continued research in AD and other neurodegenerative diseases, including Huntington's Disease.